Graphite Bio appoints Kimberlee Drapkin as independent director

LENZ Therapeutics, Inc.

Board expanded from 10 to 11; Drapkin appointed effective July 28, 2023.
Drapkin has 25+ years biotech/pharma experience; formerly CFO at Jounce Therapeutics.
She will receive cash and equity under Director Compensation Policy, prorated from appointment.
No arrangements or family relationships with other directors or executive officers.
She serves on boards of Acumen Pharmaceuticals, Imugene, and Kineta.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kimberlee C. Drapkin

director

LENZ · LENZ Therapeutics, Inc.

Effective: 2023-07-28
Filed: August 2, 2023, 7:59 PM ET

On July 28, 2023, the Board of Directors (the “Board”) of Graphite Bio, Inc. (the “Company”) increased the size of the Board from ten to eleven members and appointed Kimberlee C. Drapkin as a director of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberlee C. Drapkin was appointed as director at LENZ Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On July 28, 2023, the Board of Directors (the “Board”) of Graphite Bio, Inc. (the “Company”) increased the size of the Board from ten to eleven members and appointed Kimberlee C. Drapkin as a director of the Company, effective immediately

View on SEC.gov

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.